Pfizer and Flynn Pharma: A long and winding road

1 min read

But in June 2018 the Competition Appeal Tribunal (CAT) set aside the CMA’s decision and biggest ever fine and in March 2020 the Court of Appeal largely upheld the CAT judgment, quashing the fines and referring the case back to the CMA. Is this the end of the road for excessive pricing cases?